Incremental Benefit and Cost-Effectiveness of High-Dose Statin Therapy in High-Risk Patients With Coronary Artery Disease | Zendy

Paul S. Chan | Zendy; Brahmajee K. Nallamothu | Zendy; Hitinder S. Gurm | Zendy; Rodney A. Hayward | Zendy; Sandeep Vijan | Zendy

Open Access

Incremental Benefit and Cost-Effectiveness of High-Dose Statin Therapy in High-Risk Patients With Coronary Artery Disease

Author(s) -

Paul S. Chan,

Brahmajee K. Nallamothu,

Hitinder S. Gurm,

Rodney A. Hayward,

Sandeep Vijan

Publication year - 2007

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.106.667683

Subject(s) - medicine , statin , coronary artery disease , myocardial infarction , quality adjusted life year , clinical trial , cost effectiveness , cardiology , revascularization , risk analysis (engineering)

Recent clinical trials found that high-dose statin therapy, compared with conventional-dose statin therapy, reduces the risk of cardiovascular events in patients with acute coronary syndromes (ACS) and stable coronary artery disease (CAD). However, the actual benefit and cost-effectiveness of high-dose statin therapy are unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research